California-based pharmaceutical giant Gilead Sciences has announced that a five-day course of its antiviral drug Remdesivir — shown in tests to effectively fight COVID-19 — will cost $3,120 to Americans with health insurance and $2,340 to those on Medicaid. Yet research published in April calculated that the drug could be produced at a profit for
Public Outcry Follows Gilead Decision to Charge $3000 for COVID Drug that Costs Pennies to Produce
To make matter worse, Remdesivir is a drug that “has had its development costs paid for, in large part, by independent donors like governments and ministries of health in China, the WHO, and the US government.”